IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/500,999

Filed:

10/01/2004

1st Inventor:

J. KAWAKAMI

For:

Process for Producing Fused Imidazole Compound, Reformatsky Reagent in Stable Form, and Process for

Producing the Same

Atty. Dkt. No.

3010 US0P

Art Unit:

1712

Examiner:

tba

Allowed:

Batch:

Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 529907076 US

DATE IN:

January 18, 2005

Itemized Papers/Items:

- 1. This Certificate of Express Mailing and Return Postcard (2 pages)
- 2. Transmittal Form (1 page), and Fee Transmittal Form (1 page X 2)
- 3. Information Disclosure Statement (1 page) with Form PTO/SB/08B (1 page), and cited references (2)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

MAIL STOP PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

on this date, 1/18/2005

Dated: 1 18/2005

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Half Day Road

Lincolnshire, IL 60069 USA

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no person	ns are required to respond to a co		on unless it displays a valid OMB control number.			
	Application Number	10/500,999				
TRANSMITTAL	Filing Date	10/01/2004				
FORM	First Named Inventor	J. KAWAKAMI				
	Art Unit	1712				
(to be used for all correspondence after initial filing)	Examiner Name	tba				
Total Number of Pages in This Submission 7	Attorney Docket Number	3010 US0P	3010 US0P			
Total Number of Fages in This Submission						
	LOSURES (Check all	that apply)	After Allowance Communication to TC			
	Drawing(s) Licensing-related Papers		Appeal Communication to Board			
			of Appeals and Interferences Appeal Communication to TC			
Amendment/Reply	Petition Petition to Convert to a		(Appeal Notice, Brief, Reply Brief)			
After Final	Provisional Application Power of Attorney, Revocation	, -	Proprietary Information			
	Change of Correspondence		Status Letter			
Extension of Time Request	Terminal Disclaimer		Other Enclosure(s) (please Identify below):			
	Request for Refund		Return Postcard; Certificate of Express Mailing; Form PTO/SB/08B;			
Information Disclosure Statement	CD, Number of CD(s)		ed References (2)			
	Landscape Table on Cl)				
Certified Copy of Priority Document(s) Rema						
Reply to Missing Parts/ or credi	rnmissioner is nereby authori: t any overpayment to Deposit	ed to charge any Account 500799	additional fees which may be required, .			
Incomplete Application Reply to Missing Parts						
under 37 CFR 1.52 or 1.53						
SIGNATURE	OF APPLICANT, ATTO	RNEY, OR A	GENT			
Firm Name Takeda Pharmaceuticals North Am	nerica, Inc.					
Signature All Charles			· · · · · · · · · · · · · · · · · · ·			
Printed name Mark Chao, Ph.D., JD						
Date 1/8/66		Reg. No. 37,2	93			
CERTIFICATE OF TRANSMISSION/MAILING						
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:						
Signature Lail L. Winsky						
Typed or printed name Gail L. Winokur	-		Date 1/18/05			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express mail #EV 524907076 US

Complete if Known

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid QMB control number.

CCC TDANICMITTAL

Mark Chas, Ph.D. JD

Name (Print/Type)

Signature

I FF HAVIADIMILI AT	Application Number 10/500,999	10/500,999				
for FY 2005	Filing Date 10/01/2004	10/01/2004				
Effective 10/01/2004. Patent fees are subject to annual revision.	First Named Inventor J. KAWAKAMI					
	Examiner Name tba	tba				
Applicant claims small entity status. See 37 CFR 1.27	Art Unit 1712					
TOTAL AMOUNT OF PAYMENT (\$) 180.00	Attorney Docket No. 3010 US0P	\supset				
METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)					
Check Credit card Money Other None						
Deposit Account:	Large Entity Small Entity					
Deposit	Fee Fee Fee Fee Fee Description Code (\$) Code (\$)	Paid				
Account Number	1051 130 2051 65 Surcharge - late filing fee or oath					
Deposit Account Takeda Chemical Ind. Ltd.	1052 50 2052 25 Surcharge - late provisional filing fee or					
Name	cover sheet 1053 130 1053 130 Non-English specification					
The Director is authorized to: (check all that apply) Charge fee(s) indicated below Credit any overpayments	1812 2,520 1812 2,520 For filing a request for ex parte reexamination]				
Charge any additional fee(s) or any underpayment of fee(s)	1804 920* 1804 920* Requesting publication of SIR prior to]				
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.	1805 1,840* 1805 1,840* Requesting publication of SIR after Examiner action					
	1251 110 2251 55 Extension for reply within first month					
FEE CALCULATION 1. BASIC FILING FEE	1252 430 2252 215 Extension for reply within second month					
Large Entity Small Entity	1253 980 2253 490 Extension for reply within third month					
Fee Fee Fee Fee Description Fee Paid	1254 1,530 2254 765 Extension for reply within fourth month					
Code (\$) Code (\$) 1001 790 2001 395 Utility filing fee	1255 2,080 2255 1,040 Extension for reply within fifth month					
1002 350 2002 175 Design filing fee	1401 340 2401 170 Notice of Appeal					
1003 550 2003 275 Plant filing fee	1402 340 2402 170 Filing a brief in support of an appeal					
1004 790 2004 395 Reissue filing fee	1403 300 2403 150 Request for oral hearing]				
1005 160 2005 80 Provisional filing fee	1451 1,510 1451 1,510 Petition to institute a public use proceeding					
SUBTOTAL (1) (\$)	1452 110 2452 55 Petition to revive - unavoidable	I				
	1453 1,330 2453 665 Petition to revive - unintentional					
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE Fee from	1501 1,370 2501 685 Utility issue fee (or reissue)					
Extra Claims below Fee Paid Total Claims 20** = X 18 =	1502 490 2502 245 Design issue fee					
Total Claims	1503 660 2503 330 Plant issue fee					
Claims - 3" =	1460 130 1460 130 Petitions to the Commissioner					
	1807 50 1807 50 Processing fee under 37 CFR 1.17(q)					
Large Entity Small Entity Fee Fee Fee Fee Fee Description	1000 100 100 Casimosian of micrimation bisologate Cana	0.00				
Code (\$) Code (\$)	8021 40 8021 40 Recording each patent assignment per property (times number of properties)					
1202 18 2202 9 Claims in excess of 20 1201 88 2201 44 Independent claims in excess of 3	1809 790 2809 395 Filing a submission after final rejection (37 CFR 1.129(a))					
1203 300 2203 150 Multiple dependent claim, if not paid	1810 790 2810 395 For each additional invention to be examined (37 CFR 1.129(b))					
1204 88 2204 44 ** Reissue independent claims over original patent	1801 790 2801 395 Request for Continued Examination (RCE)					
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent	1802 900 1802 900 Request for expedited examination of a design application	$-\parallel$				
	Other fee (specify)					
*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 180.00						
SUBMITTED BY	(Complete (if applicable))	=				

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Registration No.

(Attorney/Agent)

37,293

Telephone 847-383-3272

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/500,999 Application No.:

Filed: 10/01/2004

1st Inventor: J. KAWAKAMI

Process for Producing Fused Imidazole Compound, For:

Reformatsky Reagent in Stable Form, and Process for

Producing the Same

Atty. Dkt. No. 3010 US0P Art Unit: 1712

Examiner:

Allowed:

Batch:

Paper No.:

Information Disclosure Statement

MAIL STOP PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached form PTO/SB/08B. A legible copy of each listed reference

(X) are enclosed.

() has been previously submitted to the Patent Office in prior patent application Serial No..

This information disclosure statement is being submitted

- () within 3 months of the filing date of the above-identified application
- () before the mailing date of the first Office Action on the merits.
- () thus, no certification or fee is required.
- (X) The Commissioner is authorized to charge any required fee or to credit any overpayment to USPTO Deposit Account 500799.

For each non-English language reference listed on the attached Form PTO-1449, reference is made to the concise explanation attached thereto.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached Form PTO-1449 be returned in accordance with MPEP §9609.

Respectfully submitted.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully invited to call applicants' attorney.

Dated:

(847)383-3372

(847)383-3391

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43032

01/25/2005 SNAJARRO 00000067 500799

10500999Attorney for Applicants

01 FC:1806

180.00 DA

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road

Lincolnshire, IL 60069 USA

Customer No. 23115

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known				
				Application Number	10/500,999	
INFORMATION DISCLOSURE				Filing Date	10/01/2004	
STATEMENT BY APPLICANT		First Named Inventor	J. KAWAKAMI			
(Use as many sheets as necessary)			ecessary)	Art Unit	1712	
(66 66 1111), 11111 11111 11111		Examiner Name	tba			
Sheet	1	of	1	Attorney Docket Number	3010 US0P	

		NON PATENT LITERATURE DOCUMENTS	~
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A1	M. MARCEL GAUDEMAR, et al., "Organic Chemistry - On the Preparation, the Structure and the Properties of Reformatsky Complexes", C.R. Acad. Sc. Paris, (January 10, 1966), t. 262, pp. 213-216 - Abstract	
	A2	M. MARCEL GAUDEMAR, et al., "Organic Chemistry - On the Reformatsky Reaction. Structure of Zinc Compounds from Ethylene Bromoacetate", C.R. Acad. Sc. Paris, (October 21, 1968), t. 267, pp. 1053-1056 - Abstract	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.